Boardroom Alpha
Start trial
10-Q primary document
ARQT · Quarterly Report (Form 10-Q) · Filed August 6, 2025

Arcutis Biotherapeutics Inc — 10-Q exhibit

exhibit103boraamendmentno2.htm
Arcutis Biotherapeutics Inc on Boardroom Alpha
Document
Exhibit 10.3
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.
AMENDMENT 2
to the
MANUFACTURING SUPPLY AGREEMENT
This Amendment (this “Amendment”) is entered into as of May 14, 2025 (“Amendment Effective Date”) between Arcutis Biotherapeutics, Inc. (“Arcutis”), and Bora Pharmaceuticals Services Inc. (“Bora”). Arcutis and Bora are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
WHEREAS, Arcutis and Bora have previously entered into a Manufacturing Supply Agreement with the execution date of November 8, 2023 (the “Agreement”); and
WHEREAS, Arcutis and Bora mutually desire to amend the terms and conditions of the Agreement.
NOW, THEREFORE, in consideration of the mutual covenants herein contained, and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each Party), and intending to be legally bound, the Parties agree as follows:
1.Definitions: Capitalized terms used in this Amendment and not otherwise defined herein shall have the meaning as defined in the Agreement.
2.Amendments to Schedule 3: Schedule 3 of the Agreement is repealed and replaced in its entirety with the Attachment 1 of this Amendment.
3.Continuation of Agreement: Except as expressly provided in this Amendment, all other terms, conditions and provisions of the Agreement shall remain in full force and effect. To the extent that there is any conflict or inconsistency between the terms of this Amendment and the Agreement, the terms of this Amendment shall supersede and prevail.
4.Governing Law: This Amendment shall be binding on the Parties and their respective successors and assigns. This Amendment shall be interpreted, construed and enforced in accordance with the laws of the State of Delaware, USA, without application of any law, rule or judicial precedent thereof that would require application of the laws of any other jurisdiction.
5.Entire Amendment: The Agreement (as amended by this Amendment) constitutes the entire agreement of the Parties hereto with respect to the subject matter, and supersedes all prior agreements and understandings, whether written or oral, with respect to the subject matter. This Amendment cannot be amended or modified except in writing, duly executed by all of the Parties.
6.Execution in Counterparts: This Amendment may be executed in counterparts, each of which shall be deemed an original but all of which taken together shall constitute one and the same instrument. A counterpart executed by any Party may be delivered to the other Parties by facsimile or scanned email attachment and such delivery shall have the full force and effect of an original signature.
[Signature page follows]


IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the Amendment Effective Date.

Bora Pharmaceuticals Services Inc.
By:/s/ Jeffrey Mowery
Name:Jeffrey Mowery
Title:Division President
Arcutis Biotherapeutics, Inc.
By:/s/ Gregory Sukay
Name:Gregory Sukay
Title:Vice President, Manufacturing & Process Technologies





ATTACHMENT 1
SCHEDULE 3
FEES
[***]

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer